Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: Clin Cancer Res. 2019 Nov 6;26(4):892–901. doi: 10.1158/1078-0432.CCR-19-0556

Figure 3. Genomic subtyping was associated with response to different chemotherapy regimens.

Figure 3.

DCR: disease control (complete response + partial response + stable disease) rate. RR: response (complete response + partial response) rate. Criterion 1: LCNEC tumors with RB1+TP53 co-alterations were classified as SCLC-like LCNEC (n=15), otherwise as NSCLC-like (n=) (39). Criterion 2: LCNEC tumors harboring any of the following alterations: RB1 mutation or loss, PTEN loss/mutation, FGFR1/FGFR4 mutation/amplification, TP53 loss were classified as SCLC-like LCNEC (n=27), otherwise as NSCLC-like (n=27). SCLC-PE: etoposide-platinum doublets. NSCLC-GEM/TAX: gemcitabine or taxane-platinum doublets. NSCLC-PEM: pemetrexed-platinum doublets. Note: Only 2 SCLC-like LCNEC patients based on criterion 1 were treated with NSCLC-GEX/TAX, who were not included in the statistical analysis.